- Report
- January 2024
- 190 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- October 2023
- 190 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Clinical Trials
- April 2024
- 450 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- January 2024
- 200 Pages
Global
From €4012EUR$4,150USD£3,448GBP
- Report
- October 2023
- 145 Pages
Global
From €3045EUR$3,150USD£2,617GBP
- Report
- November 2023
- 306 Pages
Global
From €3480EUR$3,600USD£2,991GBP
- Report
- November 2020
- 450 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- August 2021
- 91 Pages
Global
From €917EUR$949USD£789GBP
- Report
- November 2022
- 154 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- June 2022
- 1500 Pages
Global
From €3770EUR$3,900USD£3,241GBP
- Report
- February 2022
- 360 Pages
United States
From €3480EUR$3,600USD£2,991GBP
- Report
- December 2020
- 120 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- July 2020
- 1200 Pages
Japan
From €2900EUR$3,000USD£2,493GBP
- Report
- February 2020
- 600 Pages
Global
From €3867EUR$4,000USD£3,324GBP
- Report
- March 2018
- 330 Pages
Global
From €2900EUR$3,000USD£2,493GBP
- Report
- January 2023
- 189 Pages
Global
From €4060EUR$4,200USD£3,490GBP
- Report
- June 2022
- 191 Pages
Global
From €3384EUR$3,500USD£2,908GBP
- Report
- January 2021
- 900 Pages
United States
From €3190EUR$3,300USD£2,742GBP
- Report
- April 2019
- 115 Pages
Global
From €1344EUR$1,390USD£1,155GBP
- Report
- March 2023
- 115 Pages
Global
From €4737EUR$4,900USD£4,071GBP
Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs.
Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated.
Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more